923 related articles for article (PubMed ID: 25350685)
1. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
Zeng H; Zhang H; Jang F; Zhao L; Zhang J
Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
[TBL] [Abstract][Full Text] [Related]
3. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
4. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
Costantino G; Macchiarulo A; Camaioni E; Pellicciari R
J Med Chem; 2001 Nov; 44(23):3786-94. PubMed ID: 11689065
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
Tripathy S; Azam MA; Jupudi S; Sahu SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
[TBL] [Abstract][Full Text] [Related]
6. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
Tripuraneni NS; Azam MA
J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1.
Fatima S; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2012 Aug; 32(4):214-24. PubMed ID: 22713102
[TBL] [Abstract][Full Text] [Related]
8. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
10. [Construction of pharmacophore model of PARP-1 inhibitor].
Zhang WT; Yan H; Jiang FC
Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827
[TBL] [Abstract][Full Text] [Related]
11. Exploring the effect of PARP-1 flexibility in docking studies.
Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
13. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
[TBL] [Abstract][Full Text] [Related]
14. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
15. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
17. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
Gohlke BO; Overkamp T; Richter A; Richter A; Daniel PT; Gillissen B; Preissner R
BMC Bioinformatics; 2015 Sep; 16():308. PubMed ID: 26403354
[TBL] [Abstract][Full Text] [Related]
18. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
Qiu Y; Zhou L; Hu Y; Bao Y
J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
[TBL] [Abstract][Full Text] [Related]
19. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations.
Dong L; Feng R; Bi J; Shen S; Lu H; Zhang J
J Mol Model; 2018 Mar; 24(4):86. PubMed ID: 29511885
[TBL] [Abstract][Full Text] [Related]
20. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
